Allt inom Q3
Nanexa publishes interim report for January – September 2023
Positive clinical and preclinical results, and secured financing with focus on NEX-22 and next steps in partner projects
Nanexa publishes interim report for January – September 2022
Launch of NEX-22 in type 2 diabetes and new partner projects with great potential